- InterView
- ‘Leclaza can occupy 50% of mkt if used as combination'
- by Jung, Sae-Im Jul 28, 2023 05:30am
- Yuhan Corp’s Leclaza (lazertinib) was the first homegrown new drug to be approved as a first-line treatment for EGFR mutation-positive non-small-cell lung cancer. The industry’s eyes are now on how the drug will fare in the global market. Will Leclaza be able to rise as a new contender to AstraZeneca’s ‘Tagrisso (osimertinib)’ that is domin
- Policy
- Maintenance of grounds for original drug price
- by Kim, Jung-Ju Jul 27, 2023 05:40am
- The government will establish a legal basis so that the insurance price of the original drug can be reduced ex officio when a generic of an original drug whose patent has expired is listed on the drug reimbursement list. It is interpreted that they are trying to respond to pharmaceutical companies by preparing a clear basis for the ex offici
- Company
- Celltrion applies for approval of its Eylea biosimilar in KR
- by Jung, Sae-Im Jul 27, 2023 05:40am
- On the 26th, Celltrion announced that it had completed applying for the marketing authorization of 'CT-P42,' its biosimilar to the eye disease treatment ‘Eylea (aflibercept).’ Based on its global Phase III trial, Celltrion applied to be approved for all Eylea indications including as a treatment for wet age-related macular degeneration
- Company
- Atozet market, ↑ 225% in 2 years
- by Chon, Seung-Hyun Jul 27, 2023 05:40am
- The hyperlipidemic complex drug Atozet prescription market has grown significantly. It more than tripled in two years due to the entry of generic drugs. About 100 generic products increased their market share to 60%, leading the market expansion. Jeil and HK inno. N stood out among generic products. According to UBIST, a pharmaceutical research
- Company
- Reimb discussions imminent for Obizur in Korea
- by Eo, Yun-Ho Jul 27, 2023 05:40am
- Takeda Pharmaceuticals Korea is quickening its steps to receive reimbursement listing for ‘Obizur,’ its treatment for bleeding episodes in patients with acquired hemophilia A (AHA). According to industry sources, Takeda Pharmaceuticals Korea’s bleeding treatment for adults with acquired hemophilia A may soon be introduced for deliberat
- Policy
- NHIS extends Bavencio’s reimb...adds KRW 20 bil sales
- by Lee, Tak-Sun Jul 27, 2023 05:40am
- Korea's 6th immuno-oncology drug, 'Bavencio Inj,’was granted a reimbursement extension and will be covered for the first-line treatment of urothelial cancer from next month. With the reimbursement extension, the drug is expected to secure annual sales worth more than KRW 10 billion like the other immuno-oncology drugs. 'Bavencio is the f
- Company
- Astellas launches urothelial cancer drug Padcev
- by Kim, Jin-Gu Jul 26, 2023 05:41am
- Astellas officially launched 'Padcev' in Korea as a drug to treat locally advanced or metastatic urothelial cancer. Astellas Pharmaceutical Korea held a press conference to commemorate the launch of Padcev in Korea at the Intercontinental Hotel in Seoul on the 19th. Urethral carcinoma is a type of bladder cancer. It is estimated that 90% of
- Company
- Acetaminophen prescriptions at a record high
- by Chon, Seung-Hyun Jul 26, 2023 05:41am
- The single-agent antipyretic analgesic ‘acetaminophen’ recorded the largest-ever sales in outpatient prescriptions. The prescription market for acetaminophen has increased significantly due to the unceasing number of confirmed COVID-19 cases arising despite the end of the COVID-19 pandemic and the increase in flu and cold patients. Th
- Company
- MSD Korea appoints Albert Kim as new managing director
- by Eo, Yun-Ho Jul 26, 2023 05:41am
- On the 25th, MSD Korea announced that it has appointed Albert Kim (pic) as the new managing director, effective August 1st. The new managing director Kim is a seasoned pharma and bio expert who has served in global and Korean pharmaceutical bio companies for more than 25 years, accumulating extensive experience in local and global markets,
- Policy
- All Sandoz products removed from Korea’s reimb list
- by Lee, Tak-Sun Jul 26, 2023 05:41am
- All products that were registered by Sandoz Korea will be removed from Korea’s reimbursement list. The company had withdrawn from the Korean market in June. With the removal, the name Sandoz will no longer be visible in the Korean market. However, a grace period of 6 months has been granted for some items, and reimbursement for such drug
